GLP-1’s Are No Longer a Fringe Benefits Issue

For a while, GLP-1’s looked like a fringe benefits issue—expensive, high-profile, and easy to file under “we’ll deal with it later.” That’s no longer the case.

For Canadian employers, especially fast-growing tech teams, GLP-1’s are becoming a real plan design decision. Not because every company suddenly needs to cover everything, and not because the category itself has become simple, but because employee demand is rising, public attention is intensifying, and the cost implications are becoming harder to ignore. In fact, GLP-1 drugs were specifically called out by plan sponsors as a growing concern, with many pointing to rapid cost escalation and increasing demand as key pressure points.

The 2025 Benefits Canada Drug Plan Opinion Survey reflects this shift, with plan sponsors increasingly focused on sustainability, rising drug costs, and the impact of high-cost medications on their plans.

Lower Costs Are Coming. The Conversation Isn’t Getting Smaller.

What makes this moment more complex is that it may arrive with lower prices, not just higher pressure.

As Health Canada reviews multiple generic semaglutide submissions, there is a growing expectation that GLP-1 access could expand in Canada. If even a few generics are approved, prices could drop significantly. Pharmacists estimate that prices could decline by 65 percent or more if multiple generic versions are approved, potentially expanding access to a much broader population of employees.

At the same time, demand is already substantial. More than one million Canadians are currently taking Ozempic, and billions are already being spent annually across this category.

For employers, this changes the dynamic.

Lower-cost access does not simplify the decision, it broadens it. What was once a niche or high-barrier benefit consideration has the potential to become a much more common employee request.

This Isn’t a Drug Trend. It’s a Plan Design Decision.

The survey data reinforces how central drug plans have become within the broader benefits strategy.

Ninety-two percent of plan sponsors say their prescription drug plan is extremely or very important. Eighty-four percent point to financial protection for employees, while 80 percent link it directly to attraction and retention. Half say it has a meaningful impact on productivity. Many also view drug plans as central to managing chronic conditions and supporting broader workforce health strategies, reinforcing how closely these decisions tie into long-term employee outcomes.

GLP-1’s sit directly within that context.

They are not simply another drug category to evaluate—they introduce questions about access, fairness, and tradeoffs within the plan itself. In many cases, they force employers to clarify what their benefits program is designed to do and where boundaries should exist.

This is particularly relevant in tech environments, where expectations can shift quickly. Increased visibility, physician recommendations, and social normalization can turn a relatively niche treatment into a widely discussed workplace topic in a short period of time.

Costs Are Rising, but Visibility Into Those Costs Is Limited

There is no question that cost pressure is increasing.

• Drug plans are now the main cost driver: 83% of employers are seeing rising costs, and more than half of total benefits spend is now tied to drugs.
• Cost increases are accelerating, not stabilizing: Mid-teen trend factors at renewal mean employers are facing consistent, double-digit year-over-year pressure.
• The real driver isn’t price—it’s usage: Increased utilization and high-cost specialty drugs are pushing costs up, often without clear visibility into why.
• Most employers lack visibility into impact: At the same time, many employers still lack clear visibility into what those costs are actually delivering. Only 11% feel confident in the health outcomes of their drug plan, with most still relying on cost and utilization—not actual results—to measure success.

This gap becomes more pronounced with categories like GLP-1’s, where demand is high, outcomes can be meaningful, and the implications of coverage decisions extend beyond pure cost.

As one industry leader put it in the report:

“GLP-1’s were a bit of a perfect storm.”

The combination of rising costs and increasing employee demand creates a scenario where decisions are not purely financial—they also carry cultural and organizational implications. 

What Changes When Generics Enter the Market

The introduction of generic semaglutide has the potential to reshape the economics of this category, but it does not remove the underlying decision for employers.

If prices decline meaningfully, more employees who were previously priced out of treatment may begin to pursue it. While this improves access, it can also increase utilization and expand the scope of the conversation within a plan. In practical terms, the question shifts from whether a plan can support a small number of high-cost claims to how it should respond when demand becomes more widespread. 

There’s also a broader dynamic at play. Drugs like Viagra and Botox were originally developed for entirely different purposes before becoming widely used across new categories. GLP-1’s are already following a similar path. While they were initially introduced for diabetes and later expanded into weight management, there are emerging use cases tied to cardiovascular health and recovery. In some cases, they are already being prescribed as part of ongoing treatment following serious events like strokes. For employers, this means the conversation isn’t static—what GLP-1’s are used for today is unlikely to be the full picture over the next few years.

What Employers Should Define Early

Before renewal cycles begin and before expectations become entrenched, there are a few key decisions that benefit from early clarity:

• Defining eligibility criteria (e.g., diabetes, weight management, or both)
• Determining whether prior authorization or step therapy will apply
• Setting category limits intentionally rather than reactively
• Aligning carrier rules with the company’s broader benefits philosophy
• Communicating the policy clearly to employees

Communication is particularly important. When plan rules are unclear or only surface at the point of claim denial, the conversation often shifts away from plan design and toward employee trust.

The Real Question Is How GLP-1’s Are Managed

The survey highlights how heavily plan sponsors rely on advisors to navigate these decisions, with 91 percent turning to their advisor for guidance and most ranking them as their most trusted source of information.

At the same time, many employers still feel they lack sufficient clarity around how emerging drug categories will impact their plans over time.

As one plan sponsor noted:

“Knowing in advance when there are big things impacting our costs would be helpful.”

That observation reflects a broader need for forward-looking plan design, rather than reactive adjustments.

GLP-1’s are unlikely to fade as a topic. Increased access and visibility will continue to bring them further into focus. The employers who navigate this well will not necessarily be the ones who move the fastest, but the ones who establish a clear approach early and align their plan design with that intent.